Shionogi Inc. manufactures Xofluza [1]. Shionogi is a Japanese pharmaceutical company [2]. It has a subsidiary in the United States called Shionogi Inc. [1].
What is Xofluza used for?
Xofluza is an antiviral medication prescribed to treat influenza (flu) in individuals aged 12 years and older [3]. It is effective against influenza A and influenza B virus infections [3]. It can also be used to prevent influenza following exposure to the virus [3].
How does Xofluza work?
Xofluza, also known by its generic name baloxavir marboxil, works by inhibiting the cap-dependent endonuclease activity of the influenza virus polymerase basic protein 2 (PB2) subunit [4]. This enzyme is crucial for the replication of the influenza virus within host cells [4]. By blocking this enzyme, Xofluza prevents the virus from making new copies of itself [4].
When does Xofluza's patent expire?
Information regarding the specific patent expiry dates for Xofluza is available on DrugPatentWatch.com [5]. Patent expiration dates are critical for determining when generic versions of a drug may become available [5].
What are the alternatives to Xofluza for flu treatment?
Other antiviral medications are available for treating influenza, including oseltamivir (Tamiflu), zanamivir (Relenza), and peramivir (Rapivab) [3]. These drugs, while belonging to a different class of antivirals (neuraminidase inhibitors), also work to inhibit viral replication [4].
What are the potential side effects of Xofluza?
Common side effects reported with Xofluza include diarrhea, nausea, and bronchitis [3]. Less common but potentially serious side effects can include hypersensitivity reactions and delirium or abnormal behavior [3]. It is important to discuss any concerns about side effects with a healthcare provider [3].